Through ANSTO, Australia is a world leader in the advanced manufacturing of diagnostic and therapeutic nuclear medicines.
Follow the journey
Every Australian is likely to benefit from nuclear medicine and on average will have at least two nuclear medicine procedures in their lifetime*.
Take a look at how nuclear medicine makes its way from ANSTO's OPAL reactor to medical centres around Australia.
On average, ANSTO’s radioisotopes provide 10,000 - 12,000 nuclear medicine procedures that benefit Australians each week*.
*based on published Medicare statistics combined with non-MBS data sourced from the nuclear medicine community
Producing nuclear medicine in Australia
The most widely used radioisotope in nuclear medicine, technetium-99 (Tc-99m), decays from its parent radioisotope molybdenum-99 (Mo-99). Mo-99 is produced in Australia by ANSTO.
Tc-99m emits very small amounts of radiation that can be detected by PET and SPECT gamma cameras. The images provide vital information to doctors on physiological processes in the body and are used to diagnose disease.
Mo-99 is produced in the multipurpose OPAL nuclear reactor, processed at ANSTO’s new Mo-99 Manufacturing Facility and despatched to practitioners in shielded Gentech® Generators manufactured by ANSTO.
ANSTO also produces a diverse range of radiochemicals to support research, industry and the manufacture of radiopharmaceuticals.